AtaGenix

Hot search： CD47 │ IL6 │ PD-L1 │ CTLA-4 │ TIGIT
Current Site： Product Center / Recombinant Protein / Drug Targets / Recombinant Human IL2RA protein ,C- His Tag

Recombinant Human IL2RA protein ,C- His Tag

  • 1
ATMP00212HU
-
+
Spot
Inquiry
  • Product Details
  • Frontier progress
  • How to order
  • Instructions
Summaryicon
English name
Recombinant Human IL2RA protein ,C- His Tag
Purity
>90% as determined by SDS-PAGE
Endotoxin level
< 1.0 EU per μg of the protein as determined by the LAL method.
Construction
A DNA sequence encoding the human IL2RA(Met1-Gln240) was fused with the C-terminal His Tag
Accession #
P01589
Host
Mammalian cells
Species
Homo sapiens (Human)
Predicted Molecular Mass
27.20 kDa
Formulation
Lyophilized. Lyophilized from PBS pH7.4，1mM EDTA, 4%trehalose，1% mannitol.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability &Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
Reconstitution
Reconstitute in sterile water for a stock solution.
SDS-PAGE imageicon
    Backgroundicon
    Background
    Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.
    Alternative Names
    IL2RA,CD25,p55,IL2-RA,IL-2-RA
    References
    Li, Ran, Xu, Luo, Song, Xu, Zhang (2020) Role of CD25 expression on prognosis of acute myeloid leukemia: A literature review and meta-analysis PloS one 15(7) e0236124
    The gene expression for interleukin-2 receptor subunit alpha (CD25/IL2RA) is frequently altered in adults with acute myeloid leukemia (AML). Increasing evidence indicates that the elevated expression of CD25 may be correlated with poor survival for AML patients. Thus, we performed this meta-analysis to further evaluate the prognostic value of elevated CD25 in AML. Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the R language 3.6.0 software, Pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/relapse-free survival (RFS)/event-free survival (EFS) for total and subgroup analyses were calculated to investigate the association of elevated CD25 and outcomes of AML patients. Ten studies with a total of 1640 participants were enrolled in this meta-analysis. Pooled HRs suggested that overexpression of CD25 predicted poor outcomes on both OS (HR = 2.27, 95%CI 1.95-2.64) and DFS/RFS/EFS (HR = 1.77, 95%CI 1.44-2.17) in overall population. Subgroup analyses stratified by ethnicity, AML subtype, cut-off value, statistical methodologies and detection method draw similar results. Our meta-analysis indicates that elevated CD25 expression is a poor prognostic factor for AML patients. Considering limited number of samples, further relevant studies are warranted.

    Guarantee and Disclaimer:

    After receiving the product, if finds that the product is mismatched, damaged or missing components, please keep the original package and submit the objection to the company by mail within seven working days. Failure to file an objection within the time limit is considered qualified.

    When the buyer keeps the product, it should be kept in accordance with the storage conditions shown in the product label and the manual. If the product quality is caused by improper storage, it will not be guaranteed.

    When the buyer tests the product, they should be submitted by the beginning of use when found the quality issue, rather than when the product was used or used up, in order to prepare our products for recycling and confirm the quality of the products. If it is the quality problem, our company is responsible for exchange or return. In the event of a claim, our company will compensate the discretion within the scope of the product price limit and will not accept any part of the value of the product itself. Since the date of receipt, the product has not been reflected for more than three months and should not be returned.

    The products provided by our company are for research use only and should not be used for clinical diagnosis or treatment. If a unit or individual changes the use of our products without authorization, we will not bear any responsibility.

    AtaGenix
    Copyright © 2024 Lawyer Theme All Rights Reserved
    Site map | Contact us | Join us